RY 172.7 -0.1792% SHOP 152.38 -3.7762% TD 74.49 -0.4144% ENB 58.66 0.2906% BN 80.21 0.2124% TRI 235.76 -0.7034% CNQ 42.27 -1.3305% CP 102.81 -2.4851% CNR 145.02 -0.9426% BMO 139.15 0.5855% BNS 77.045 -0.149% CSU 4497.2998 0.6756% CM 92.23 -0.335% MFC 43.28 0.8858% ATD 79.0 -1.1882% NGT 53.35 -1.8038% TRP 65.26 0.215% SU 49.61 -1.411% WCN 251.65 -0.2181% L 191.14 0.1205%
Last update at 2024-12-19T17:17:00Z
Breakdown | 2023-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 |
---|---|---|---|---|
Type | yearly | yearly | yearly | yearly |
Date | 2023-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 |
Income before tax | -15.54585M | -4.47364M | -4.47364M | -1.35065M |
Minority interest | - | - | - | - |
Net income | -15.60291M | -4.37202M | -4.37202M | -1.92415M |
Selling general administrative | 24.16M | 5.73M | 9.57M | 1.65M |
Selling and marketing expenses | - | - | - | - |
Gross profit | 22.53M | 5.96M | 5.96M | 0.33M |
Reconciled depreciation | 2.48M | 0.84M | 0.84M | 0.05M |
Ebit | - | - | - | - |
Ebitda | - | - | - | - |
Depreciation and amortization | - | - | - | - |
Non operating income net other | - | - | - | - |
Operating income | -6.13180M | -0.60795M | -4.45068M | -1.31104M |
Other operating expenses | - | - | - | - |
Interest expense | 2.64M | 0.39M | 0.39M | - |
Tax provision | 0.06M | -0.10162M | -0.10162M | 0.00000M |
Interest income | - | - | - | - |
Net interest income | -2.63999M | -0.38806M | -0.38806M | - |
Extraordinary items | - | - | - | - |
Non recurring | - | - | - | - |
Other items | - | - | - | - |
Income tax expense | - | - | - | - |
Total revenue | 62.63M | 18.31M | 18.31M | 0.35M |
Total operating expenses | 68.76M | 18.92M | 22.76M | 1.66M |
Cost of revenue | 40.09M | 12.35M | 12.35M | 0.02M |
Total other income expense net | -6.77406M | -3.47763M | 0.37M | -0.03961M |
Discontinued operations | - | - | - | - |
Net income from continuing ops | -15.60291M | -4.37202M | -4.37202M | -1.35065M |
Net income applicable to common shares | - | - | - | - |
Preferred stock and other adjustments | - | - | - | - |
Breakdown | 2023-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 |
---|---|---|---|---|
Type | yearly | yearly | yearly | yearly |
Date | 2023-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 |
Total assets | 48.26M | 42.68M | 13.13M | 9.73M |
Intangible assets | 7.03M | 6.93M | - | - |
Earning assets | - | - | - | - |
Other current assets | - | - | - | - |
Total liab | 44.25M | 29.53M | 6.49M | 0.23M |
Total stockholder equity | 4.00M | 13.15M | 6.64M | 9.50M |
Deferred long term liab | - | - | - | - |
Other current liab | 10.90M | 13.56M | 5.44M | 0.01M |
Common stock | - | - | - | - |
Capital stock | 53.51M | 38.53M | 31.07M | 31.06M |
Retained earnings | -64.86420M | -33.36488M | -28.99286M | -26.32544M |
Other liab | - | - | - | - |
Good will | 6.40M | 9.83M | 0.00000M | - |
Other assets | - | - | - | - |
Cash | 0.92M | 8.06M | 7.08M | 8.35M |
Cash and equivalents | - | - | - | - |
Total current liabilities | 37.57M | 23.16M | 6.49M | 0.23M |
Current deferred revenue | - | - | - | - |
Net debt | 15.86M | - | - | - |
Short term debt | - | - | - | - |
Short long term debt | 16.52M | 5.67M | - | - |
Short long term debt total | - | - | - | - |
Other stockholder equity | - | - | - | - |
Property plant equipment | - | - | - | - |
Total current assets | 21.00M | 20.04M | 13.13M | 9.73M |
Long term investments | - | - | - | - |
Net tangible assets | - | - | - | - |
Short term investments | - | 0.00000M | 0.49M | 0.84M |
Net receivables | 7.80M | 6.36M | 0.00000M | 0.00000M |
Long term debt | 0.26M | 0.68M | - | - |
Inventory | 10.24M | 4.97M | 0.00000M | - |
Accounts payable | 6.91M | 2.86M | 0.48M | 0.17M |
Total permanent equity | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - |
Accumulated other comprehensive income | - | - | - | - |
Additional paid in capital | - | - | - | - |
Common stock total equity | - | - | - | - |
Preferred stock total equity | - | - | - | - |
Retained earnings total equity | - | - | - | - |
Treasury stock | - | - | - | - |
Accumulated amortization | - | - | - | - |
Non currrent assets other | - | - | - | - |
Deferred long term asset charges | - | - | - | - |
Non current assets total | 27.25M | 22.65M | 0.00000M | 0.00000M |
Capital lease obligations | 7.91M | 4.18M | 0.00000M | - |
Long term debt total | - | - | - | - |
Breakdown | 2023-11-30 | 2022-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-11-30 | 2022-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 |
Investments | -1.51885M | - | -4.61754M | -4.61754M | -0.89941M |
Change to liabilities | - | - | - | - | - |
Total cashflows from investing activities | - | - | - | - | - |
Net borrowings | - | - | - | - | - |
Total cash from financing activities | 0.82M | - | 3.94M | 3.94M | 0.00000M |
Change to operating activities | - | - | - | - | - |
Net income | -15.60291M | -19.07569M | -4.37202M | -2.66742M | -1.92415M |
Change in cash | -1.61322M | - | -4.38626M | -4.38626M | -1.09702M |
Begin period cash flow | 1.93M | 8.06M | 12.51M | 12.51M | 9.30M |
End period cash flow | 0.92M | 1.93M | 8.06M | 8.06M | 8.35M |
Total cash from operating activities | -0.91891M | - | -3.70388M | -3.70388M | -0.19761M |
Issuance of capital stock | - | - | 4.26M | 4.26M | - |
Depreciation | 2.48M | - | 0.84M | 0.84M | 0.05M |
Other cashflows from investing activities | - | - | - | - | - |
Dividends paid | - | - | - | - | - |
Change to inventory | 4.65M | - | 0.25M | 0.25M | - |
Change to account receivables | -1.90155M | - | -2.06588M | -2.06588M | - |
Sale purchase of stock | - | - | - | - | - |
Other cashflows from financing activities | - | - | - | - | - |
Change to netincome | - | - | - | - | - |
Capital expenditures | 0.20M | 0.00000M | 0.06M | 0.06M | 0.00000M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | -0.92490M | - | -0.20620M | -0.20620M | 0.75M |
Stock based compensation | 1.29M | - | 1.20M | 1.20M | 0.02M |
Other non cash items | -2.39341M | - | -5.65086M | -5.65086M | - |
Free cash flow | -1.12218M | - | -3.75914M | -3.75914M | -0.19761M |
Sector: Healthcare Industry: Medical Devices
Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
EVMT Evome Medical Technologies Inc. |
-0.02 14.81% | 0.12 | - | - | 0.19 | 2.56 | 0.49 | -2.6149 |
TLT Theralase Technologies Inc. |
- -% | 0.27 | - | - | 77.35 | 42.96 | 77.25 | -12.0585 |
PINK Perimeter Medical Imaging AI Inc |
-0.015 3.61% | 0.40 | - | - | 57.28 | 2.90 | 43.60 | -2.5521 |
ASG Aurora Spine Corp |
-0.005 1.16% | 0.42 | - | - | 1.92 | 4.83 | 1.60 | 46.70 |
VPT VentriPoint Diagnostics Ltd |
- -% | 0.10 | - | - | 320.99 | 7.13 | 333.50 | -6.6788 |
Evome Medical Technologies Inc. develops, manufactures, and distributes medical devices and products in the Americas and internationally. The company's product portfolio includes various devices for pain management and physical therapy treatments, including isokinetic dynamometers, perturbation gait trainers, balance assessment and recovery devices, neuromuscular electrical and transcutaneous electrical nerve stimulation devices, ultrasound treatment devices, wearable technology, and other products designed for the prevention, treatment, and rehabilitation of the human body. It offers SpaceTek Knee Device, a portable compact dynamometer isokinetic testing and rehabilitation device designed for small clinics; and Reactive Step Trainer that provides reproducible task-specific step perturbation to physical therapists, athletic trainers, orthopedic surgeons, hospitals, universities, research centers and healthcare distributors. In addition, the company offers assembly, packaging, and printing solutions to medical, construction, consumer products, and original equipment manufacturer companies. Further, it provides end-to-end solutions for medical device supply chains, including production, packaging, and servicing, as well as repair services; services for mechanical and electrical design and engineering, design and human factors, software and web development, and applied research and algorithm development; and products and supplies for capital equipment furnishings, capital equipment modalities, preventative care, and injury and rehabilitation to athletic trainers, physical therapists, and sports institutions. Additionally, the company offers design layout services to hospitals, private practice, rehabilitation, long-term care, and sports medicine markets. The company was formerly known as Salona Global Medical Device Corporation and changed its name to Evome Medical Technologies Inc. in January 2024. Evome Medical Technologies Inc. is headquartered in Shirley, New York.
49 Natcon Drive, Shirley, NY, United States, 11967-4704
Name | Title | Year Born |
---|---|---|
Mr. Michael Seckler | CEO & Executive Director | 1966 |
Ms. Cherine Pottinger-Harris | Principal Accounting Officer & Interim Chief Financial Officer | 1981 |
Mr. William Hauer | Vice President of Marketing & Sales | NA |
Ms. Heydi Benson | Director of Human Resources | NA |
Mr. Jethro Rothe-Kushel | Vice President of Capital Markets & Financial Communications | NA |
Jeffrey Chu | Executive Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.